Therapeutic or Preventive Procedure
Nimbus Therapeutics Announces Leadership Transition: Abbas Kazimi Appointed as New CEO
Nimbus Therapeutics, CEO transition, Abbas Kazimi, Jeb Keiper, biotechnology, computational drug discovery
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
targeted protein degradation, neurodegenerative diseases, TRIM21, TRIMTAC degraders, CNS therapeutics, seed funding, biotech startup
Senators grill Trump’s NIH nominee on vaccines and funding
United States National Institutes of Health, Vaccines, Bhattacharya, Senators, Trump ‘s, Senators, research
Persica Reports Positive Phase 1b Results for Novel Antibiotic Treatment in Chronic Low Back Pain
Persica Pharmaceuticals, PP353, chronic low back pain, antibiotic therapy, Modic changes, Phase 1b clinical trial
J&J’s Shockwave Medical Launches Novel Javelin Intravascular Lithotripsy Catheter for Treating Calcified Peripheral Artery Disease
Intravascular lithotripsy, peripheral artery disease, calcified lesions, Shockwave Medical, Johnson & Johnson, medical device, vascular intervention
Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care
Cancer immunotherapy, Targeted therapies , Precision medicine, AI in oncology, Combination treatments, Biosimilars, Clinical trial design, Personalized cancer care
Pliant Therapeutics Discontinues Phase 2b/3 Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis Due to Safety Concerns
Pliant Therapeutics, bexotegrast, BEACON-IPF trial, idiopathic pulmonary fibrosis (IPF), safety concerns, clinical trial discontinuation
Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer
Multi-payload ADCs, antibody-drug conjugates, oncology, HER2-targeted therapy, dual-payload technology, cancer treatment, biotechnology startup
Eikon pulls in $351M as lead drug begins Phase III journey
Eikon Therapeutics Secures $351M Funding for Cancer Drug Development Eikon Therapeutics raised $351 million in a Series D funding round124 Total funding raised since 2019 launch now exceeds $1.1 billion1 Lead drug EIK1001 has entered Phase III trials for advanced melanoma14 Clinical studies ongoing in 28 countries across 5 continents14 ## Pipeline Highlights: EIK1001: TLR7/8 […]
Eikon pulls in $351M as lead drugs begins Phase III journey
Eikon Therapeutics Secures $350.7 Million Series D to Advance Cancer Drug Pipeline Eikon Therapeutics, a pivotal-stage biotechnology company, has raised $350.7 million in a Series D financing round to support its clinical-stage programs and future pipeline development147. This significant funding brings Eikon’s total capital raised since its founding in 2019 to over $1.1 billion17. ## […]